Reshuffle backlash to challenge KPMA unity

Published: 2009-02-23 07:00:00

Updated: 2009-02-23 07:00:00

As the proposed revision of article of incorporation in the Korea Pharmaceutical Manufacturers Association has failed to attract any support from many members of small- and medium-sized pharmaceutical firms, the KPMA is facing a potential crisis that could trigger a dispute between large and smal...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK